BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

August 10, 2016 9:54 AM EDT
Get Alerts VRX Hot Sheet
Price: $21.98 +1.81%

Rating Summary:
    12 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 20 | New: 30
Trade VRX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

BTIG affirms Valeant Phama (NYSE: VRX) at Neutral following Q2 results from the company.

Analyst Timothy Chiang commented, While quarterly results were mixed, the Co. maintained its full year financial targets (which include revenues of $9.9 - $10.1B and EPS of $6.60 - $7.00). While the tone of management seems to have taken a more positive turn, we are still cautious on the stock and believe the Co.’s recovery is still largely a work-in-progress.

We remain Neutral rated on VRX shares, and believe the path to a full recovery will take longer than just 6 months to execute. On one hand, we think new CEO Joe Papa may be getting his hands more around the issues that plague the Co., which could be beneficial for the shares. However, on the other hand, based on the weaker than expected 2Q results and the sizeable YOY declines seen in the Co’s dermatology and eye care Rx segments, we believe a rapid recovery in 2H16 could be an overly optimistic scenario without significant buy-in from patients with Valeant’s products.

BTIG's outlook for CY16 and CY17 EPS is $6.57 and $7.89, respectively.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities


Add Your Comment